Group Purchasing Organization (GPO) of generic pharmaceuticals
On behalf of parties seeking to combine their purchasing of generic pharmaceuticals, co-led a team in performing detailed economic analysis to assess whether the expanded Group Purchasing Organization would have anticompetitive buyer market power, also referred to as monopsony power. Work included an analysis of the combined share of the two parties in each product, an examination of the ability of manufacturers to switch productive assets to alternative uses, and an assessment of the bargaining strength of buyers and sellers. The transaction was finalized in May 2017.